Integrated Environmental Technologies 10-Q 3 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 01, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	INTEGRATED ENVIRONMENTAL TECHNOLOGIES, LTD.
Entity Central Index Key	1,084,031
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		304,164,263
Trading Symbol	IEVM
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 978,976	$ 371,292
Accounts receivable	73,616	37,098
Prepaid expenses	11,611	11,780
Inventory	$ 150,741	117,690
Other receivable		111,200
Total current assets	$ 1,214,944	649,060
Property and equipment, net	271,556	259,468
Total assets	1,486,500	908,528
Current liabilities:
Accounts payable	326,700	154,167
Accrued expenses	202,066	403,520
Customer deposits	2,000	2,000
Convertible debentures	501,125	501,125
Note payable	6,766	46,546
Total current liabilities	1,038,657	1,107,358
Stockholders' equity (deficiency):
Common stock, $.001 par value; 600,000,000 shares authorized; 304,164,263 and 253,178,774 shares issued and outstanding, respectively	304,164	253,179
Additional paid-in capital	23,581,154	21,262,811
Accumulated deficit	(23,437,475)	(21,714,820)
Total stockholders' equity (deficiency)	447,843	(198,830)
Total liabilities and stockholders' equity (deficiency)	$ 1,486,500	$ 908,528

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	304,164,263	253,178,774
Common stock, shares outstanding	304,164,263	253,178,774

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Sales	$ 151,545	$ 42,382	$ 295,622	$ 54,444
Leasing and licensing fees	6,000	6,000	12,000	12,000
Total revenues	157,545	48,382	307,622	66,444
Cost of sales	52,411	27,486	108,840	31,731
Gross profit	105,134	20,896	198,782	34,713
Operating expenses:
General and administrative	446,286	279,582	1,033,995	577,059
Sales and marketing	249,837	121,855	672,519	282,222
Research and development	59,169	51,001	193,179	111,891
Total operating expenses	755,292	452,438	1,899,693	971,172
Loss from operations	(650,158)	$ (431,542)	(1,700,911)	$ (936,459)
Other income (expense):
Interest income	271		390
Interest expense	(11,123)	$ (12,735)	(22,134)	$ (25,017)
Total other income (expense)	(10,852)	(12,735)	(21,744)	(25,017)
Net loss	$ (661,010)	$ (444,277)	$ (1,722,655)	$ (961,476)
Net loss per share, basic and diluted	$ 0	$ 0	$ (0.01)	$ 0
Weighted average shares outstanding, basic and diluted	304,160,495	230,778,176	291,746,739	230,602,520

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (1,722,655)	$ (961,476)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	46,965	42,708
Stock-based compensation expense	443,378	49,188
Changes in operating assets and liabilities:
Accounts receivable	(36,518)	478
Inventory	(68,276)	(864)
Prepaid expenses	169	$ 15,248
Other receivable	111,200
Accounts payable	184,533	$ 88,949
Accrued expenses	$ (201,454)	$ 1,659
Customer deposits
Net cash used in operating activities	$ (1,242,658)	$ (764,110)
Cash flows used in investing activity:
Purchase of equipment	(23,828)
Cash flows from financing activities:
Proceeds from sale of common stock, net of offering costs	1,913,950	$ 25,200
Repayment of note payable	(39,780)	(30,825)
Net cash provided by (used in) financing activities	1,874,170	(5,625)
Increase (decrease) in cash	607,684	(769,735)
Cash - beginning of period	371,292	1,049,399
Cash - end of period	978,976	279,664
Supplemental disclosure of cash flow information:
Cash paid for interest	1,504	4,119
Cash paid for income taxes	900	700
Noncash operating activity:
Issuance of 171,428 and 206,250 shares of common stock, respectively, as payment of director fees	12,000	$ 16,500
Parts and materials inventory used in production equipment	35,225
Issuance of 1,055,303 shares of common stock as payment of offering costs related to private placements	56,000
Issuance of warrants to purchase 1,450,303 shares of common stock as payment of offering costs related to private placements	$ 47,100

Consolidated Statements of Cas6

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Statement of Cash Flows [Abstract]
Common stock issued as payment of director fees	171,428	206,250
Common stock issued as payment offering costs related to private placements	1,055,303
Issuance of warrant to purchase of common stock shares as payment of offering costs related to private placements	1,450,303

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had working capital of $176,287 and an accumulated deficit of $23,437,475 as of June 30, 2015. The Company also has no lending relationships with commercial banks and is dependent on the completion of financings involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company does not anticipate establishing any lending relationships with commercial banks in the foreseeable future due to its limited operations and assets. The Company continues to execute its primary strategy of selling its anolyte disinfecting solution under the Excelyte® brand name to fund its operations and is focused on obtaining additional capital through the private placement of its securities. The Company is pursuing potential equity and/or debt investors and, from time to time, has engaged placement agents to assist it in this initiative. While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts. If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company. Any additional equity financing may result in substantial dilution to the Company’s stockholders.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory	2. Inventory As of June 30, 2015 and December 31, 2014, inventory consisted of parts and materials totaling $150,741 and $117,690, respectively.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment As of June 30, 2015 and December 31, 2014, property and equipment, on a net basis, consisted of the following: June 30, 2015 December 31, 2014 Leasehold improvements $ 330,953 $ 328,977 Equipment 494,581 437,504 825,534 766,481 Less: Accumulated depreciation (553,978 ) (507,013 ) $ 271,556 $ 259,468

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses As of June 30, 2015 and December 31, 2014, accrued expenses consisted of the following: June 30, 2015 December 31, 2014 Accrued compensation $ 116,455 $ 253,305 Accrued penalty — 87,344 Accrued interest (see Note 5) 47,697 27,321 Accrued professional fees 2,750 22,000 Accrued consulting fees and other expenses 35,164 13,550 $ 202,066 $ 403,520

Convertible Debentures

Convertible Debentures	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Convertible Debentures	5. Convertible Debentures April 2007 Convertible Debenture On April 26, 2007, in a private placement, the Company issued a convertible debenture to an individual accredited investor in the principal amount of $25,000. This convertible debenture matured on January 2, 2009 and remains unpaid. The convertible debenture accrues interest at a rate of 12% per annum and is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.40 per share. An aggregate of 62,500 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on this convertible debenture at the current conversion price of $0.40 per share. During each of the three and six months ended June 30, 2015 and 2014, the Company recorded a total of $740 and $1,488, respectively, of interest expense related to this convertible debenture. As of June 30, 2015 and December 31, 2014, the outstanding principal on this convertible debenture was $25,000, which was included as a component of convertible debentures, and the accrued and unpaid interest was $14,929 and $13,441, respectively, which was included as a component of accrued expenses (see Note 4). Zanett Convertible Debentures On August 21, 2012, the Company issued to Zanett Opportunity Fund, Ltd. (“Zanett”) an 8% convertible debenture in the amount of $476,125 (the “Zanett August 2012 Debenture”). In connection with this private placement, the Company refinanced an 8% convertible debenture, in the principal amount of $376,125, issued to Zanett on July 7, 2011 (the “Zanett July 2011 Debenture”) and refinanced an 8% convertible secured promissory note, in the principal amount of $100,000, issued to Zanett on September 23, 2011 (the “Zanett September 2011 Note”). As a result of the issuance of the Zanett August 2012 Debenture, the Zanett July 2011 Debenture and the Zanett September 2011 Note were cancelled. The Zanett August 2012 Debenture has a three-year term maturing on August 21, 2015 and bears interest at a rate of 8% per annum. Interest is payable in annual installments in cash or, at the option of the Company, in shares of the Company’s common stock. If the Company elects to pay the interest in shares of its common stock, the number of shares issued as payment will be equal to the quotient of the unpaid interest divided by the market price of the Company’s common stock, as defined in the Zanett August 2012 Debenture. The entire principal amount of the Zanett August 2012 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.10 per share. In addition, at the option of the Company, the entire principal amount of the Zanett August 2012 Debenture is convertible into shares of the Company’s common stock at $0.10 per share upon the occurrence of the merger or acquisition of the Company or if the average closing price of the Company’s common stock for any period of ten consecutive trading days is greater than or equal to $0.15 per share. The quoted market price of the Company’s common stock on August 21, 2012 was $0.05 per share. An aggregate of 4,761,250 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on the Zanett August 2012 Debenture at the current conversion price of $0.10 per share. During each of the three and six months ended June 30, 2015 and 2014, the Company recorded $9,496 and $18,888, respectively, of interest expense related to the Zanett August 2012 Debenture. As of June 30, 2015 and December 31, 2014, the outstanding principal on the Zanett August 2012 Debenture was $476,125, which was included as a component of convertible debentures, and the accrued and unpaid interest was $32,768 and $13,880, respectively, which was included as a component of accrued expenses (see Note 4).

Note Payable

Note Payable	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Note Payable	6. Note Payable On June 17, 2013, the Company and Benchmark Performance Group, Inc. (“Benchmark”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), whereby the Company purchased nineteen EcaFlo® machines owned by Benchmark as well as the rights to the Excelyte® trademark and certain other intangible assets. The purchase price for the nineteen EcaFlo® machines, the Excelyte® trademark and other intangible assets was $190,000. The Company paid $38,000 in conjunction with the closing of the Asset Purchase Agreement and issued a promissory note with a principal balance of $152,000 (the “Benchmark Note”). The Benchmark Note bears interest at a rate of 7% per annum and requires the Company to make twenty-four monthly payments of $6,805 commencing August 1, 2013. The Benchmark Note is secured by the nineteen EcaFlo® machines. For the three and six months ended June 30, 2015, the Company recorded $353 and $1,053, respectively, of interest expense related to the Benchmark Note. For the three and six months ended June 30, 2014, the Company recorded $1,706 and $3,735, respectively, of interest expense related to the Benchmark Note. As of June 30, 2015 and December 31, 2014, the outstanding principal on the Benchmark Note was $6,766 and $46,546, respectively.

Stockholders' Equity (Deficienc

Stockholders' Equity (Deficiency)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders' Equity (Deficiency)	7. Stockholders’ Equity (Deficiency) Common Stock On April 3, 2015, the Company issued an aggregate of 171,428 shares of its common stock, at a per share price of $0.07, as settlement of $12,000 of director fees due certain members of the Company’s board of directors for services rendered for the period commencing July 1, 2014 through December 31, 2014. The quoted market price of the Company’s common stock on April 3, 2015, the date the issuance was approved by the Company’s board of directors, was $0.07 per share. Stock Options The Company currently has two stock option/stock compensation plans in place: the 2010 Stock Incentive Plan and the 2012 Equity Incentive Plan (collectively, the “Equity Incentive Plans”). The 2010 Stock Incentive Plan was approved by the stockholders in September 2010. The Company had reserved for issuance an aggregate of 10,000,000 shares of common stock under the 2010 Stock Incentive Plan. As of June 30, 2015, stock options to purchase 3,846,920 shares of the Company’s common stock were outstanding under the 2010 Stock Incentive Plan and 90,500 shares of the Company’s common stock had been issued under the 2010 Stock Incentive Plan. As a result of the adoption of the Company’s 2012 Equity Incentive Plan, no further awards are permitted under the 2010 Stock Incentive Plan. The 2012 Equity Incentive Plan was approved by the stockholders in May 2012. The 2012 Equity Incentive Plan is designed to encourage and enable employees and directors of the Company to acquire or increase their holdings of common stock and other proprietary interests in the Company. The 2012 Equity Incentive Plan is intended to promote these individuals’ interests in the Company, thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company. The 2012 Equity Incentive Plan provides for grants and/or awards in the form of incentive and non-qualified stock option grants, stock appreciation rights, restricted stock awards, performance share awards, phantom stock awards and dividend equivalent awards. The original aggregate number of shares of common stock which could be awarded under the 2012 Equity Incentive Plan was 14,000,000 shares, subject to adjustment as provided in the 2012 Equity Incentive Plan. Effective February 25, 2015, as permitted under the 2012 Equity Incentive Plan, the Company’s board of directors increased the number of shares of common stock that could be awarded under the 2012 Equity Incentive Plan to 37,950,000 shares. As of June 30, 2015, options to purchase 2,518,150 shares of the Company’s common stock were outstanding under the 2012 Equity Incentive Plan and up to 35,431,850 shares of the Company’s common stock remain available for awards under the 2012 Equity Incentive Plan. Common stock grants and stock option awards under the Equity Incentive Plans were granted or issued at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company’s common stock on the date of grant or issuance. Stock options granted and outstanding to date consist of both incentive stock options and non-qualified stock options. A summary of stock option transactions under the Equity Incentive Plans during the six months ended June 30, 2015 is set forth below: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2014 4,846,920 $ 0.15 $ — Granted during the period 2,518,150 $ 0.07 — Exercised during the period — — — Terminated during the period (1,000,000 ) $ 0.09 — Outstanding at June 30, 2015 6,365,070 $ 0.13 $ — Exercisable at June 30, 2015 5,482,534 $ 0.14 $ — Exercisable at December 31, 2014 3,846,920 $ 0.16 $ — The fair value of stock options granted during the six months ended June 30, 2015 was $101,762 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions: Exercise price $0.07 - $0.08 Grant date stock price $0.07 - $0.076 Expected volatility 128% - 137 % Risk-free interest rates 1.26% - 2.08 % Risk of forfeiture 35 % Expected life (in years) 5 - 10 Dividend yield 0.00 % The risk-free interest rate is based on a treasury instrument, the term of which is consistent with the expected life of the stock options at the date of grant. In projecting expected stock price volatility, the Company used historical stock price volatility of its common stock which the Company believes is representative of future volatility. The Company estimated the expected life of stock options based on historical experience using employee exercise and option expiration data. Information with respect to stock options outstanding and stock options exercisable as of June 30, 2015 is as follows: Stock Options Exercisable Stock Options Outstanding Number of Exercise Prices Number of Shares Available Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Shares Available for Purchase Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 0.07 2,068,150 $ 0.07 4.8 1,548,114 $ 0.07 4.8 $ 0.08 450,000 $ 0.08 9.7 87,500 $ 0.08 9.7 $ 0.10 2,180,253 $ 0.10 3.7 2,180,253 $ 0.10 3.7 $ 0.20 833,333 $ 0.20 6.8 833,333 $ 0.20 6.8 $ 0.30 833,334 $ 0.30 6.8 833,334 $ 0.30 6.8 6,365,070 $ 0.13 3.0 5,482,534 $ 0.14 5.0 A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of June 30, 2015 is as follows: Stock Option Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2014 1,000,000 $ 0.09 Granted during the period 2,518,150 $ 0.07 Vested during the period (1,635,614 ) $ 0.07 Terminated during the period (1,000,000 ) $ 0.09 Non-vested at June 30, 2015 882,536 $ 0.07 As of June 30, 2015, there was $32,893 of total unrecognized compensation cost related to non-vested, stock-based compensation arrangements granted under the Equity Incentive Plans. That cost is expected to be recognized over a weighted average period of twenty-three months. Warrants to Purchase Common Stock A summary of warrant transactions during the six months ended June 30, 2015 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2014 28,908,878 $ 0.12 $ 42,006 Issued during the period 5,238,183 $ 0.065 — Exercised during the period — — — Terminated during the period (11,706,250 ) $ 0.13 — Outstanding at June 30, 2015 22,440,811 $ 0.10 $ 3,459 Exercisable at June 30, 2015 22,440,811 $ 0.10 $ 3,459 Exercisable at December 31, 2014 28,908,878 0.12 $ 42,006 Warrants issued by the Company contain exercise prices that were approved by the Company’s board of directors. Such exercise prices are generally not less than the quoted market price of the Company’s common stock on the date of issuance. Warrants currently issued either vested immediately or over a period of up to three years and have a maximum term of ten years from the date of issuance. The fair value of the warrants issued during the six months ended June 30, 2015 was $168,813 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions: Exercise price $0.06 - $0.066 Grant date stock price $0.067 Expected volatility 128 % Risk-free interest rates 0.87 % Risk of forfeiture 35 % Expected life (in years) 3 Dividend yield 0.00 % Information with respect to warrants outstanding and warrants exercisable at June 30, 2015 is as follows: Warrants Exercisable Warrants Outstanding Number of Range of Exercise Prices Number of Shares Available Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share Shares Available for Purchase Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share $ 0.03 - 0.04 1,151,567 1.5 $ 0.04 1,151,567 1.5 $ 0.04 $ 0.06 - 0.07 10,344,244 3.9 $ 0.07 10,344,244 3.9 $ 0.07 $ 0.08 - 0.09 6,320,000 5.8 $ 0.09 6,320,000 5.8 $ 0.09 $ 0.20 4,625,000 0.2 $ 0.20 4,625,000 0.2 $ 0.20 22,440,811 3.6 $ 0.10 22,440,811 3.6 $ 0.10 As of June 30, 2015, there were no non-vested shares subject to warrants and no unrecognized compensation cost related to warrants.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation During the three and six months ended June 30, 2015 and 2014, the Company recorded stock-based compensation expense as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 General and administrative $ 66,894 $ 15,111 $ 254,251 $ 41,948 Sales and marketing 1,396 2,548 132,951 5,068 Research and development — 1,092 56,176 2,172 $ 68,290 $ 18,751 $ 443,378 $ 49,188 For the three and six months ended June 30, 2015, the Company recorded stock-based compensation expense related to common stock and stock options granted to employees and directors of $68,290 and $443,378, respectively. For the three and six months ended June 30, 2015, the Company did not record any stock-based compensation expense for non-employees. For the three and six months ended June 30, 2014, the Company recorded stock-based compensation expense related to stock options granted to employees and directors of $7,280 and $17,717, respectively. For the three and six months ended June 30, 2014, the Company recorded stock-based compensation expense related to common stock and warrants granted to non-employees of $11,471 and $31,471, respectively.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Common Share	9. Net Loss Per Common Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. For the three and six months ended June 30, 2015, diluted net loss per share did not include the effect of 6,365,070 shares of common stock issuable upon the exercise of outstanding stock options, 22,440,811 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive. For the three and six months ended June 30, 2014, diluted net loss per share did not include the effect of 4,680,254 shares of common stock issuable upon the exercise of outstanding stock options, 37,344,565 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Litigation with Former Executive Vice President - Operations On June 17, 2014, a civil complaint was filed against the Company and one of its directors, E. Wayne Kinsey, III, in the Court of Common Pleas, County of Horry, State of South Carolina, by Marion Sofield, the Company’s former Executive Vice President - Operations. In her complaint, Ms. Sofield alleges breach of contract and fraud/fraudulent inducement by the Company against her with regard to her employment agreement and the termination of her employment. Ms. Sofield also alleges the Company and Mr. Kinsey engaged in a civil conspiracy and unfair trade practices and that Mr. Kinsey engaged in tortious interference. Ms. Sofield claims that she is owed additional compensation under her terminated employment agreement, and is seeking the recovery of such compensation as well as attorney’s fees and punitive damages. On July 18, 2014, the Company filed a motion to dismiss this state court action due to the binding arbitration clause contained in Ms. Sofield’s employment agreement that applies to a majority of the allegations in the complaint. On December 8, 2014, the court entered a consent order that: (a) granted the Company’s request to compel binding arbitration of the breach of contract and fraud claims; and (b) stayed the remaining causes of action in the South Carolina state court until the aforementioned binding arbitration process is complete. The Company does not believe there is any merit to Ms. Sofield’s allegations and will continue to vigorously defend this action.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Components of Property and Equipment, on Net Basis	As of June 30, 2015 and December 31, 2014, property and equipment, on a net basis, consisted of the following: June 30, 2015 December 31, 2014 Leasehold improvements $ 330,953 $ 328,977 Equipment 494,581 437,504 825,534 766,481 Less: Accumulated depreciation (553,978 ) (507,013 ) $ 271,556 $ 259,468

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses	As of June 30, 2015 and December 31, 2014, accrued expenses consisted of the following: June 30, 2015 December 31, 2014 Accrued compensation $ 116,455 $ 253,305 Accrued penalty — 87,344 Accrued interest (see Note 5) 47,697 27,321 Accrued professional fees 2,750 22,000 Accrued consulting fees and other expenses 35,164 13,550 $ 202,066 $ 403,520

Stockholders' Equity (Deficie19

Stockholders' Equity (Deficiency) (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Stock Option Transactions	A summary of stock option transactions under the Equity Incentive Plans during the six months ended June 30, 2015 is set forth below: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2014 4,846,920 $ 0.15 $ — Granted during the period 2,518,150 $ 0.07 — Exercised during the period — — — Terminated during the period (1,000,000 ) $ 0.09 — Outstanding at June 30, 2015 6,365,070 $ 0.13 $ — Exercisable at June 30, 2015 5,482,534 $ 0.14 $ — Exercisable at December 31, 2014 3,846,920 $ 0.16 $ —
Summary of Fair Value Assumption of Stock Options Granted Using Black-Scholes Pricing Model	The fair value of stock options granted during the six months ended June 30, 2015 was $101,762 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions: Exercise price $0.07 - $0.08 Grant date stock price $0.07 - $0.076 Expected volatility 128% - 137 % Risk-free interest rates 1.26% - 2.08 % Risk of forfeiture 35 % Expected life (in years) 5 - 10 Dividend yield 0.00 %
Summary of Stock Options Outstanding and Exercisable	Information with respect to stock options outstanding and stock options exercisable as of June 30, 2015 is as follows: Stock Options Exercisable Stock Options Outstanding Number of Exercise Prices Number of Shares Available Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Shares Available for Purchase Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 0.07 2,068,150 $ 0.07 4.8 1,548,114 $ 0.07 4.8 $ 0.08 450,000 $ 0.08 9.7 87,500 $ 0.08 9.7 $ 0.10 2,180,253 $ 0.10 3.7 2,180,253 $ 0.10 3.7 $ 0.20 833,333 $ 0.20 6.8 833,333 $ 0.20 6.8 $ 0.30 833,334 $ 0.30 6.8 833,334 $ 0.30 6.8 6,365,070 $ 0.13 3.0 5,482,534 $ 0.14 5.0
Summary of Non Vested Stock Options Granted	A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of June 30, 2015 is as follows: Stock Option Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2014 1,000,000 $ 0.09 Granted during the period 2,518,150 $ 0.07 Vested during the period (1,635,614 ) $ 0.07 Terminated during the period (1,000,000 ) $ 0.09 Non-vested at June 30, 2015 882,536 $ 0.07
Summary of Warrant Transactions	A summary of warrant transactions during the six months ended June 30, 2015 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2014 28,908,878 $ 0.12 $ 42,006 Issued during the period 5,238,183 $ 0.065 — Exercised during the period — — — Terminated during the period (11,706,250 ) $ 0.13 — Outstanding at June 30, 2015 22,440,811 $ 0.10 $ 3,459 Exercisable at June 30, 2015 22,440,811 $ 0.10 $ 3,459 Exercisable at December 31, 2014 28,908,878 0.12 $ 42,006
Summary of Warrants Outstanding and Exercisable	Information with respect to warrants outstanding and warrants exercisable at June 30, 2015 is as follows: Warrants Exercisable Warrants Outstanding Number of Range of Exercise Prices Number of Shares Available Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share Shares Available for Purchase Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share $ 0.03 - 0.04 1,151,567 1.5 $ 0.04 1,151,567 1.5 $ 0.04 $ 0.06 - 0.07 10,344,244 3.9 $ 0.07 10,344,244 3.9 $ 0.07 $ 0.08 - 0.09 6,320,000 5.8 $ 0.09 6,320,000 5.8 $ 0.09 $ 0.20 4,625,000 0.2 $ 0.20 4,625,000 0.2 $ 0.20 22,440,811 3.6 $ 0.10 22,440,811 3.6 $ 0.10
Warrant [Member]
Summary of Fair Value Assumption of Stock Options Granted Using Black-Scholes Pricing Model	The fair value of the warrants issued during the six months ended June 30, 2015 was $168,813 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions: Exercise price $0.06 - $0.066 Grant date stock price $0.067 Expected volatility 128 % Risk-free interest rates 0.87 % Risk of forfeiture 35 % Expected life (in years) 3 Dividend yield 0.00 %

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation	During the three and six months ended June 30, 2015 and 2014, the Company recorded stock-based compensation expense as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 General and administrative $ 66,894 $ 15,111 $ 254,251 $ 41,948 Sales and marketing 1,396 2,548 132,951 5,068 Research and development — 1,092 56,176 2,172 $ 68,290 $ 18,751 $ 443,378 $ 49,188

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ 176,287
Accumulated deficit	$ 23,437,475	$ 21,714,820

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory	$ 150,741	$ 117,690

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment, on Net Basis (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 330,953	$ 328,977
Equipment	494,581	437,504
Property and equipment, Gross	825,534	766,481
Less: Accumulated depreciation	(553,978)	(507,013)
Property and equipment, net	$ 271,556	$ 259,468

Accrued Expenses - Components o

Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued compensation	$ 116,455	$ 253,305
Accrued penalty		87,344
Accrued interest (see Note 5)	$ 47,697	27,321
Accrued professional fees	2,750	22,000
Accrued consulting fees and other expenses	35,164	13,550
Accrued liabilities, total	$ 202,066	$ 403,520

Convertible Debentures (Details

Convertible Debentures (Details Narrative) - USD ($)	Aug. 21, 2012	Apr. 26, 2007	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Sep. 23, 2011	Jul. 07, 2011
Debt Instrument [Line Items]
Interest expense related to convertible debenture			$ 740	$ 740	$ 1,488	$ 1,488
Convertible debenture outstanding principal			25,000		25,000		$ 25,000
Accrued and unpaid interest on convertible debt			$ 14,929		$ 14,929		13,441
Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture, maturity date					Aug. 21, 2015
Convertible debenture, interest rate			8.00%		8.00%
Convertible debenture, conversion price	$ 0.10		$ 0.10		$ 0.10
Common stock issued as payment on principal and interest on convertible debentures, shares	4,761,250
Interest expense related to convertible debenture			$ 9,496	$ 9,496	$ 18,888	$ 18,888
Convertible debenture outstanding principal			476,125		476,125		476,125
Accrued and unpaid interest on convertible debt			$ 32,768		$ 32,768		$ 13,880
Debenture term					3 years
Common stock price per share	$ 0.05		$ 0.10		$ 0.10
Zanett August 2012 Debenture [Member] | Maximum [Member]
Debt Instrument [Line Items]
Common stock price per share			$ 0.15		$ 0.15
Private Placement [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount		$ 25,000
Convertible debenture, maturity date		Jan. 2, 2009
Convertible debenture, interest rate		12.00%
Convertible debenture, conversion price		$ 0.40
Common stock issued as payment on principal and interest on convertible debentures, shares		62,500
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Debenture [Member] | Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount	$ 476,125
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Debenture [Member] | Zanett July 2011 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount									$ 376,125
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Secured Promissory Note [Member] | Zanett September 2011 Note [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount								$ 100,000

Note Payable (Details Narrative

Note Payable (Details Narrative)	Jun. 17, 2013USD ($)Machine	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Interest expense related to benchmark note		$ 740	$ 740	$ 1,488	$ 1,488
Note payable outstanding principal balance		6,766		6,766		$ 46,546
Asset Purchase Agreement [Member]
Debt Instrument [Line Items]
Number of machines purchase | Machine	19
Purchase price of asset	$ 190,000
Payment in closing of asset purchase agreement	38,000
Issuance of promissory note principal balance	$ 152,000
Convertible promissory notes, interest percentage	7.00%
Description of payment term	Twenty-four monthly payments.
Periodic payment	$ 6,805
Convertible promissory notes, commencing date	Aug. 1, 2013
Interest expense related to benchmark note		353	$ 1,706	1,053	$ 3,735
Note payable outstanding principal balance		$ 6,766		$ 6,766		$ 46,546

Stockholders' Equity (Deficie27

Stockholders' Equity (Deficiency) (Details Narrative) - USD ($)	Apr. 03, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of stock options granted		$ 101,762
Fair value of warrants		$ 168,813
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period		3 years
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period		10 years
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved		10,000,000
Issuance of stock option to purchases of common stock shares		3,846,920
Common stock stock shares issued under plan		90,500
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock stock shares issued under plan		14,000,000
Issuance of common stock shares as stock-based compensation		37,950,000
Number of common stock shares award under plan		2,518,150
Unrecognized compensation cost related to non-vested		$ 32,893
Recognized non vested over a weighted average period		23 months
Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares issued for settlement of directors fees	171,428
Common stock price per share	$ 0.07
Number of common stock issued for settlement of directors fees	$ 12,000
Common stock quoted market price per share	$ 0.07
Board of Directors [Member] | 2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares increased under plan		35,431,850

Stockholders' Equity (Deficie28

Stockholders' Equity (Deficiency) - Summary of Stock Option Transactions (Details) - 6 months ended Jun. 30, 2015 - USD ($) None in scaling factor is -9223372036854775296	Total
Equity [Abstract]
Stock Option Outstanding, Number, Beginning Balance	4,846,920
Stock Option Granted during the period, Shares	2,518,150
Stock Option Exercised during the period, Shares
Stock Option Terminated during the period, Shares	(1,000,000)
Stock Option Outstanding shares, Ending balance	6,365,070
Stock Option Exercisable, Beginning balance	3,846,920
Stock Option Exercisable, Ending balance	5,482,534
Stock Option Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 0.15
Stock Option Grants in Period, Weighted Average Exercise Price	$ 0.07
Stock Option Exercises in Period, Weighted Average Exercise Price
Stock OptionTerminated, Weighted Average Exercise Price	$ 0.09
Stock Option Outstanding, Weighted Average Exercise Price, Ending balance	0.13
Stock Option Exercisable, Weighted Average Exercise Price, Beginning balance	0.16
Stock Option Exercisable, Weighted Average Exercise Price, Ending balance	$ 0.14
Stock Option Outstanding, Aggregate Intrinsic Value, Beginning balance
Stock Option Granted Aggregate Intrinsic Value
Stock Option Exercised Aggregate Intrinsic Value
Stock Option Outstanding, Aggregate Intrinsic Value, Ending balance
Stock Option Exercisable, Intrinsic Value Beginning balance
Stock Option Exercisable, Intrinsic Value Ending balance

Stockholders' Equity (Deficie29

Stockholders' Equity (Deficiency) - Summary of Fair Value Assumption of Stock Options Granted Using Black-Scholes Pricing Model (Details) - Jun. 30, 2015 - $ / shares	Total
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	128.00%
Expected volatility, maximum	137.00%
Risk-free interest rates	1.26%
Risk-free interest rates	2.08%
Risk of forfeiture	35.00%
Dividend yield	0.00%
Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.07
Grant date stock price	$ 0.07
Expected life (in years)	5 years
Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.08
Grant date stock price	$ 0.076
Expected life (in years)	10 years
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date stock price	$ 0.067
Expected volatility	128.00%
Risk-free interest rates	0.87%
Risk of forfeiture	35.00%
Expected life (in years)	3 years
Dividend yield	0.00%
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.06
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.066

Stockholders' Equity (Deficie30

Stockholders' Equity (Deficiency) - Summary of Stock Options Outstanding and Exercisable (Details) - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Available Under Outstanding Stock Options	6,365,070	4,846,920
Weighted Average Exercise Price Per Common Share	$ 0.13	$ 0.15
Weighted Average Remaining Contractual Life (Years)	3 years
Number of Shares Available for Purchase Under Outstanding Stock Options	5,482,534	3,846,920
Weighted Average Exercise Price Per Common Share	$ 0.14	$ 0.16
Weighted Average Remaining Contractual Life (Years)	5 years
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.07
Number of Shares Available Under Outstanding Stock Options	2,068,150
Weighted Average Exercise Price Per Common Share	$ 0.07
Weighted Average Remaining Contractual Life (Years)	4 years 9 months 18 days
Number of Shares Available for Purchase Under Outstanding Stock Options	1,548,114
Weighted Average Exercise Price Per Common Share	$ 0.07
Weighted Average Remaining Contractual Life (Years)	4 years 9 months 18 days
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.08
Number of Shares Available Under Outstanding Stock Options	450,000
Weighted Average Exercise Price Per Common Share	$ 0.08
Weighted Average Remaining Contractual Life (Years)	9 years 8 months 12 days
Number of Shares Available for Purchase Under Outstanding Stock Options	87,500
Weighted Average Exercise Price Per Common Share	$ 0.08
Weighted Average Remaining Contractual Life (Years)	9 years 8 months 12 days
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.10
Number of Shares Available Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$ 0.10
Weighted Average Remaining Contractual Life (Years)	3 years 8 months 12 days
Number of Shares Available for Purchase Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$ 0.10
Weighted Average Remaining Contractual Life (Years)	3 years 8 months 12 days
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.20
Number of Shares Available Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$ 0.20
Weighted Average Remaining Contractual Life (Years)	6 years 9 months 18 days
Number of Shares Available for Purchase Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$ 0.20
Weighted Average Remaining Contractual Life (Years)	6 years 9 months 18 days
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.30
Number of Shares Available Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$ 0.30
Weighted Average Remaining Contractual Life (Years)	6 years 9 months 18 days
Number of Shares Available for Purchase Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$ 0.30
Weighted Average Remaining Contractual Life (Years)	6 years 9 months 18 days

Stockholders' Equity (Deficie31

Stockholders' Equity (Deficiency) - Summary of Non Vested Stock Options Granted (Details) - 6 months ended Jun. 30, 2015 - $ / shares	Total
Equity [Abstract]
Stock Option Nonvested, Number, Beginning Balance	1,000,000
Stock Option Granted during the period	2,518,150
Stock Option Vested during the period	(1,635,614)
Stock Option Terminated during the period	(1,000,000)
Stock Option Non-vested Balance	882,536
Stock Option Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance	$ 0.09
Stock Option Weighted Average Grant Date Fair Value Per Share, Granted	0.07
Stock Option Weighted Average Grant Date Fair Value Per Share, Vested	0.07
Stock Option Weighted Average Grant Date Fair Value Per Share, Terminated	0.09
Stock Option Weighted Average Grant Date Fair Value Per Share, Ending Balance	$ 0.07

Stockholders' Equity (Deficie32

Stockholders' Equity (Deficiency) - Summary of Warrant Transactions (Details) - 6 months ended Jun. 30, 2015 - Warrant [Member] - USD ($)	Total
Warrant Shares Outstanding	28,908,878
Warrant Shares Issued during the period	5,238,183
Warrant Shares Exercised during the period
Warrant Shares Terminated during the period	(11,706,250)
Warrant Shares Outstanding	22,440,811
Warrant Shares Exercisable Beginning Balance	22,440,811
Warrant Shares Exercisable Ending Balance	28,908,878
Weighted Average Exercise Price Per Common Share Outstanding	$ 0.12
Weighted Average Exercise Price Per Common Share Issued during the period	$ 0.065
Weighted Average Exercise Price Per Common Share Exercised during the period
Weighted Average Exercise Price Per Common Share Terminated during the period	$ 0.13
Weighted Average Exercise Price Per Common Share Outstanding	0.10
Weighted Average Exercise Price Per Common Share Exercisable Beginning Balance	0.12
Weighted Average Exercise Price Per Common Share Exercisable Ending Balance	$ 0.10
Aggregate Intrinsic Value Outstanding Beginning Balance	$ 42,006
Aggregate Intrinsic Value Issued during the period
Aggregate Intrinsic Value Exercised during the period
Aggregate Intrinsic Value Terminated during the period
Aggregate Intrinsic Value Outstanding Ending Balance	$ 3,459
Aggregate Intrinsic Value Exercisable Beginning Balance	42,006
Aggregate Intrinsic Value Exercisable Ending Balance	$ 3,459

Stockholders' Equity (Deficie33

Stockholders' Equity (Deficiency) - Summary of Warrants Outstanding and Exercisable (Details) - Jun. 30, 2015 - Warrant [Member] - $ / shares	Total
Number of Shares Available Under Outstanding Stock Options/ Warrants	22,440,811
Weighted Average Remaining Contractual Life (Years)	3 years 7 months 6 days
Weighted Average Exercise Price Per Common Share	$ 0.10
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	22,440,811
Weighted Average Remaining Contractual Life (Years)	3 years 7 months 6 days
Weighted Average Exercise Price Per Common Share	$ 0.10
Range One [Member]
Range of Exercise Prices, Lower Limit	0.03
Range of Exercise Prices, Upper Limit	$ 0.04
Number of Shares Available Under Outstanding Stock Options/ Warrants	1,151,567
Weighted Average Remaining Contractual Life (Years)	1 year 6 months
Weighted Average Exercise Price Per Common Share	$ 0.04
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	1,151,567
Weighted Average Remaining Contractual Life (Years)	1 year 6 months
Weighted Average Exercise Price Per Common Share	$ 0.04
Range Two [Member]
Range of Exercise Prices, Lower Limit	0.06
Range of Exercise Prices, Upper Limit	$ 0.07
Number of Shares Available Under Outstanding Stock Options/ Warrants	10,344,244
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 24 days
Weighted Average Exercise Price Per Common Share	$ 0.07
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	10,344,244
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 24 days
Weighted Average Exercise Price Per Common Share	$ 0.07
Range Three [Member]
Range of Exercise Prices, Lower Limit	0.08
Range of Exercise Prices, Upper Limit	$ 0.09
Number of Shares Available Under Outstanding Stock Options/ Warrants	6,320,000
Weighted Average Remaining Contractual Life (Years)	5 years 9 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.09
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	6,320,000
Weighted Average Remaining Contractual Life (Years)	5 years 9 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.09
Range Four [Member]
Range of exercise prices	$ 0.20
Number of Shares Available Under Outstanding Stock Options/ Warrants	4,625,000
Weighted Average Remaining Contractual Life (Years)	2 months 12 days
Weighted Average Exercise Price Per Common Share	$ 0.20
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	4,625,000
Weighted Average Remaining Contractual Life (Years)	2 months 12 days
Weighted Average Exercise Price Per Common Share	$ 0.20

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock-based compensation expense related to stock options and warrants	$ 68,290	$ 18,751	$ 443,378	$ 49,188
Employees and Director [Member]
Stock-based compensation expense related to stock options and warrants	68,290	7,280	443,378	17,717
Non-employees [Member]
Stock-based compensation expense related to stock options and warrants	$ 0	$ 11,471	$ 0	$ 31,471

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 68,290	$ 18,751	$ 443,378	$ 49,188
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	66,894	15,111	254,251	41,948
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,396	2,548	132,951	5,068
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense		$ 1,092	$ 56,176	$ 2,172

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Outstanding Stock Options [Member]
Anti-dilutive	6,365,070	4,680,254
Outstanding Warrants [Member]
Anti-dilutive	22,440,811	37,344,565
Conversion of Convertible Debt [Member]
Anti-dilutive	4,823,750	4,823,750